English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

We conducted a molecular biological investigation to determine the outcomesof hyperthermic intraperitoneal chemotherapy (HIPEC) treatment, and whether itis effective in all cases for patients with peritoneal dissemination of coloncancer. In the HIPEC group, the 3-year survival rate was 39.2%, whereas in thenon-HIPEC group the 3-year survival rate was 15.6%. MUC2 expression was investigatedin the HIPEC group, in patients positive for MUC2 expression, and the 3-year survivalrate was 0.0%, while in patients negative for MUC2 expression, the 3-year survivalrate was 61.1%. In addition, as a result of introducing MUC2-siRNA into a coloncancer cell line with high expression of the MUC2 gene, the cell death rate fromheat and anticancer agents increased 40% in comparison with colon cancer cellsin which scrambled siRNA had not been introduced. HIPEC therapy is thought tobe effective in prolonging survival in patients with peritoneal disseminationof colon cancer, and MUC2 expression is thought to be useful as an indicator toassess its effectiveness in colon cancer cells.

international journal of oncology

MUC2 protein expression status is useful in assessing the effects of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of colon cancer